IL17A and psoriasis: Despite its efficacy for the treatment of moderate to severe psoriasis, it does not achieve PASI 90 or PASI 100 response rates comparable to those of IL-17 or IL-23 inhibitors, and it has not been directly compared with adalimumab or ustekinumab.